A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets. Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have Premarket Application (“PMA”) approval, or 510(k) clearance from the United States Food and Drug Administration (“FDA”). Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease. We offer our differentiated products and in-house customer support to a wide range of health care customers including hospitals, wound care centers, government facilities, ambulatory surgery centers (“ASCs”) and physician offices.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 564M | 564M | 482M | 433M | 451M | 467M |
| Net Income | 20M | 20M | -937K | 4.9M | 16M | 95M |
| EPS | $0.15 | $0.15 | $-0.01 | $0.04 | $0.12 | $0.70 |
| Free Cash Flow | -24M | -24M | 4.2M | 6.6M | -9.0M | 31M |
| ROIC | 12.5% | 50.6% | -0.4% | 2.9% | 7.8% | 42.1% |
| Gross Margin | - | - | - | 75.4% | 76.7% | 75.6% |
| Debt/Equity | 0.11 | 0.11 | 0.01 | 0.24 | 0.29 | 0.31 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 45M | 45M | -1.3M | 13M | 22M | 72M |
| Operating Margin | 7.9% | 7.9% | -0.3% | 2.9% | 4.9% | 15.5% |
| ROE | 6.7% | 7.1% | -0.4% | 1.8% | 6.1% | 49.5% |
| Shares Outstanding | 133M | 133M | 94M | 124M | 129M | 136M |
Organogenesis Holdings Inc. passes 4 of 9 quality checks, suggesting mixed fundamentals.
Organogenesis Holdings Inc. trades at 16.7x trailing earnings, compared to its 15-year median P/E of 27.9x, suggesting it is currently Fair relative to its historical range. The company's 5-year average ROIC is 20.6% with a gross margin of 75.9%. At current prices, the estimated annualized return to fair value is -15.2%.
Organogenesis Holdings Inc. (ORGO) has a current P/E ratio of 16.7, compared to its historical median P/E of 27.9. The stock is currently considered Fair based on its historical valuation range.
Organogenesis Holdings Inc. (ORGO) has a 5-year average return on invested capital (ROIC) of 20.6%. This indicates strong capital allocation and a potential competitive advantage.
Organogenesis Holdings Inc. (ORGO) has a market capitalization of $335M. It is classified as a small-cap stock.
Organogenesis Holdings Inc. (ORGO) does not currently pay a regular dividend.
Based on historical P/E analysis, Organogenesis Holdings Inc. (ORGO) appears fair. The current P/E of 16.7 is 40% below its historical median of 27.9. The estimated fair value CAGR (P/E method) is -12.0%.
Organogenesis Holdings Inc. (ORGO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Organogenesis Holdings Inc. (ORGO) reported annual revenue of $564 million in its most recent fiscal year, based on SEC EDGAR filings.
Organogenesis Holdings Inc. (ORGO) has a net profit margin of 3.5%. This is a modest margin.
Organogenesis Holdings Inc. (ORGO) generated $-24 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Organogenesis Holdings Inc. (ORGO) has a debt-to-equity ratio of 0.11. This indicates a conservatively financed balance sheet.
Organogenesis Holdings Inc. (ORGO) reported earnings per share (EPS) of $0.15 in its most recent fiscal year.
Organogenesis Holdings Inc. (ORGO) has a return on equity (ROE) of 7.1%. This indicates moderate shareholder returns.
Organogenesis Holdings Inc. (ORGO) has a 5-year average gross margin of 75.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 10 years of financial data for Organogenesis Holdings Inc. (ORGO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Organogenesis Holdings Inc. (ORGO) has a book value per share of $2.25, based on its most recent annual SEC filing.